Using current methodologies, drug delivery to small airways, terminal bronchioles, and alveoli (deep lung) is inefficient, especially to the lower lungs. Urgent lung pathologies such as acute respiratory distress syndrome (ARDS) and post-lung transplantation complications are difficult to treat, in part due to the methodological limitations in targeting the deep lung with high efficiency drug distribution to the site of pathology. To overcome drug delivery limitations inhibiting the optimization of deep lung therapy, isolated rat Sertoli cells preloaded with chitosan nanoparticles were use to obtain a high-density distribution and concentration (92%) of the nanoparticles in the lungs of mice by way of the peripheral venous vasculature rather than the more commonly used pulmonary route. Additionally, Sertoli cells were preloaded with chitosan nanoparticles coupled with the anti-inflammatory compound curcumin and then injected intravenously into control or experimental mice with deep lung inflammation. By 24 h postinjection, most of the curcumin load (ϳ90%) delivered in the injected Sertoli cells was present and distributed throughout the lungs, including the perialveloar sac area in the lower lungs. This was based on the high-density, positive quantification of both nanoparticles and curcumin in the lungs. There was a marked positive therapeutic effect achieved 24 h following curcumin treatment delivered by this Sertoli cell nanoparticle protocol (SNAP). Results identify a novel and efficient protocol for targeted delivery of drugs to the deep lung mediated by extratesticular Sertoli cells. Utilization of SNAP delivery may optimize drug therapy for conditions such as ARDS, status asthmaticus, pulmonary hypertension, lung cancer, and complications following lung transplantation where the use of high concentrations of anti-inflammatory drugs is desirable, but often limited by risks of systemic drug toxicity.
INTRODUCTION
is therapy intended to address pathology in the small airways, terminal bronchioles, and alveoli (i.e., deep lung), especially in the lower lungs. Additional chal-Drug delivery to diseased organs, such as the lungs, is challenging, especially when the delivery of the thera-lenges are associated with the elimination of excipients that sometimes contribute to toxicities. peutic agent is limited or when there is an urgent need to insure high-density, location-specific distribution of Historically, aerosol formulations have not been able to transport medication to deep lung efficiently, particu-the drug. Pulmonary delivery of therapeutic drugs is a safe drug delivery route, especially for asthma and larly if there is severe obstruction from airway edema, mucus plugging, and/or interstitial edema. Metered dose chronic obstructive pulmonary diseases (COPDs), and provides a number of benefits particularly with regard inhalers (MDIs), breath-activated dry powder inhalers (DPIs), liquid jet, and ultrasonic nebulizers are not prac-to absorption area and avoidance of first pass metabolism in the liver (13, 16, 18, 26) . However, meeting the tical for the delivery of most macromolecules because of their low system efficiency, low drug mass per puff, sustained drug release goal can be somewhat problematic (14, 16, 18, 26) . The lungs tend to expel materials that poor formulation stability for macromolecules, and poor dosing reproducibility (4). The ideal particle size of in-are introduced via the airway and it is, therefore, difficult to keep the drug in the lung long enough for the haled medication should range from 1 to 3 µm in diameter for optimal deposition efficiency to small airways sustained release to be effective when the key challenge and terminal bronchioles (14, 15) . Particles smaller than with curcumin, a naturally occurring anti-inflammatory compound, to the deep lungs in mice by preloading the this size may reach the alveoli but are quickly expelled during exhalation. Most existing aerosol systems, al-nanoparticles into isolated SCs and then injecting these preloaded SCs into the lateral tail vein of the recipient though effectively delivering the dispensed drug to the upper airways, only deliver a small percentage of the mouse. To test the therapeutic effect of a drug delivered by the Sertoli cell nanoparticle (SNAP) protocol, oval-dispensed drug in the correct particle size for optimal deposition in the deep lung (23). Furthermore, the bumin (OVA) sensitized and challenged mice exhibiting pulmonary perivascular inflammation were treated with amount of drug deposited from the device is highly dependent on the patient's inhalation technique. The effec-SNAP-delivered curcumin. We hypothesized that curcumin delivered in this way would quickly and efficiently tive delivery of proteins and peptides is optimized only if the patient acquires the ability to inhale correctly (17).
produce a high concentration and broad distribution of the drug to the deep lung, resulting in an effective deep Most aerosol systems today deliver a total amount of <100 Cg of drug per puff to the deep lung; this amount lung therapeutic event. is too low to enable timely delivery of many macromole-MATERIALS AND METHODS cules for the often required milligram-level doses (7, 15) .
Preparation of Chitosan Nanoparticles Although recently there have been numerous positive developments advancing the effective delivery of drugs Chitosan (CS, Vanson, Redmond, WA) molecular to the lungs by nanoparticles, the aggressive and effiweight of 60,000 kDa was used to prepare the nanoparcient physiological defense system designed to rid the ticles by ionotropic gelation with negatively charged triairway system of particulate and foreign matter is an polyphosphatesodium (TPP) ions according to a preongoing obstacle to effective delivery of therapeutic naviously reported procedure (27). Briefly, CS was noparticles to the lung, especially the deep lung (15) .
dissolved in an aqueous solution of acetic acid at con-A novel approach to deliver nanoparticles coupled centrations of 0.05, 0.10, 0.15, and 0.20 wt %. The conwith drugs to the deep lung is to utilize a biocompatible centration of acetic acid was 1.75 times as high as that cell-based system to implement delivery by way of the of CS. For example, 0.10 wt % CS solution was preperipheral vasculature instead of the pulmonary route. pared in 0.175 wt % acetic acid solution. Then, 1.0 ml A successful protocol would optimize drug volume and of TPP solution was added drop wise to 0.5 ml of CS delivery and more efficiently target the deep lung with solution in a 20-ml glass vial under magnetic stirring at high drug density distribution while avoiding the liver 600 (20 rpm measured by a tachometer using an octagoand the active protease and immunoprotective environnal stirring bars). The mixture was stirred for an addiment of the lung. Testis-derived Sertoli cells (SCs) may tional 10 min. The weight ratios of CS/TPP were 4:1, be an ideal cell type to accomplish these goals. Isolated 4.5:1, 5:1, 5.5:1 and 6:1. At least five batches of CS NPs Sertoli cells have been used for over a decade to faciliwere obtained from each protocol. tate cell transplantation therapy without themselves re-Labeling Chitosan Nanoparticle With FITC sulting in deleterious effects in the host (8, 19) . They provide for the immunoprotection of allo-and xenoge-Dehydrated methanol (100 ml), followed by 2.0 mg/ml of FITC (Fluorescein-C6-Amine Labeling Kit, PANVERA, neic cell transplants and avoid immune rejection by not succumbing to either cell-or antibody-mediated immune Madison, WI) was added into 1% w/v chitosan hydrochloride in 0.1 M acetic acid solution (100 ml) with stir-responses (5, 6, 8, 20, 25) .
One reported mechanism by which SCs immunopro-ring at 1000 rpm at ambient temperature. After 3 h of reaction in the dark at ambient temperature, the fluores-tect cell grafts is by the induction of donor-specific tolerance in the host following the IV injection of xenoge-cent-labeled chitosan was precipitated in 0.2 M NaOH and separated from unreacted label using dialysis mem-neic SCs (19). In this protocol, the large SCs (ϳ30-50 µm) appear to become entrapped in the precapillary pul-brane MWCO:12-14,000 with flat width of 45 mm with 1/15 M phosphate buffer/0.2 M NaCl (pH 5.5) as elution monary vascular bed where the cells are quickly cleared from the system without apparent detrimental effects to solvent and dialyzed in 100 ml of distilled water for 3 days in the dark (1). The labeled nanoparticles were the individual. On the basis of this observation and as a means to optimize deep lung delivery of therapeutic characterized and used for uptake studies immediately upon preparation. TPP, acetic acid, FITC, chlorproma-drugs, we tested the capability of the aggressively phagocytic SCs to carry therapeutic nanoparticles to the zine, filipin, sucrose, Triton X-100, and methanol were purchased from Sigma Chemical Co. (St. Louis, MO), pulmonary parenchyma by way of the peripheral venous vasculature and then the pulmonary arterial vasculature. and dialysis membrane MWCO:12-14,000 with flat width 45 mm was purchased from Spectrum Labora-In this project we describe the delivery of chitosan nanoparticles (10) and chitosan nanoparticles coupled tories Inc. (Rancho Dominguez, CA). The transport me-dium was composed of Hanks balanced salt solution for the detection of florescence utilizing the Olympus MVX10 florescence macroscope. Some tissues were (HBSS), buffered with 10 mM N-2-hydroxyethylpiperazine-N′-2-ethanosulfonic acid (HEPES) and adjusted to processed for specific UV spectroscopic absorption assay (see below). pH 6.2 with 1.0 M HCl and purchased from Sigma.
In addition to normal mice, some female C57BL/6 Sertoli Cell Isolation and Preparation and BALB/c mice (Jackson Laboratory) were sensitized by IP injection of 10 µl OVA with alum as previously Sertoli cells were isolated from prepubertal Sprague-Dawley rat testes by sequential enzymatic digestion as described to mimic acute inflammatory allergic asthma (22, 24) . The mice were challenged weekly for 3 weeks previously reported (3, 9) and maintained in DMEM/F12 supplemented with insulin-transferrin-selenium (ITS, 0.1%, with an intranasal (IN) injection of 25 µl OVA (20 mg/ ml). One hour after the last IN challenge, the treatment Sigma) and gentamicin sulfate (50 mg/ml, Sigma). Some SCs were tagged (i.e., prelabeled SCs) with either the group (n = 7) was injected via the tail vein with SCs (8 × 10 6 ) preloaded with nanoparticles coupled with a 6.25 DiO or DiI (Molecular Probes) fluorescent cell markers as specified by the company. Some SCs were incubated mg/µl curcumin dose. Other OVA-challenged mice were not injected with SCs and served as untreated controls with FITC-labeled chitosan nanoparticles that were phagocytosed by the SCs (i.e., preloaded SCs). The na-(n = 7). Lungs from treated (experimental) and untreated (control) OVA-challenged mice were collected 24 h noparticles (500 µl, 0.5 mg/ml) were added directly to the medium and incubated with the SCs for 12 h and postinjection, evaluated morphologically, and assayed for curcumin by specific UV absorbance assay (see below). then aggressively washed (five times) with medium to remove nanoparticles not phagocytosed. All prelabeled and/or preloaded SCs were imaged utilizing the Olym-Detection of Labels pus IX71 inverted florescent microscopy to verify nano-Fluorescent labels were determined by specific UV particle phagocytosis and to define the fluorescent image spectroscopic absorbance assay in SCs only and in tisprofiles of the prelabeled and/or preloaded SCs.
sues collected from experimental (SC injected) and control (uninjected) mice. Whole organs and tissues were Project Design, Animals, Tissue Collection, homogenized in DI water, filtered, and the filtrated was and Morphological Evaluation use for the detection of labels at specific wave lengths The use of rats (to isolate SCs) and normal and OVAand quantified by the absorbance assay. Absorbance valchallenged mice conformed to approved IACUC protoues were obtained by UV spectrometry. Label detection cols for the animals. Rat SCs (8 × 10 6 ) preloaded with for DiI prelabeled SCs (red) was performed at 553 nm. nanoparticles and/or prelabeled were injected into recip-Detection of SCs preloaded with FITC-labeled nanoparient normal mice (C57BL/6 and BALB/c mice, Harlan) ticles (green) was performed at 488 nm for FITC. SCs through the lateral tail vein in a total volume 150 µl preloaded and prelabeled were assayed by specific UV culture medium following approved Institutional guideabsorption at wave lengths specific for the nanoparticle lines as previously reported (19). Tissues and organs label and the SC label. were collected from SC-injected mice (experimental, n = 12) and uninjected mice (controls, n = 4) 15 min, 1
Identification of Curcumin h, and 24 h postinjection. Some mice were injected only with SCs prelabeled with either DiO (green when
The specific UV absorbance value for curcumin was determined in SCs preloaded with curcumin-coupled na-viewed through FITC filter) or DiI (red when viewed through the TRITC filter). Some mice were injected noparticles as well as in the lungs from treated OVAchallenged mice (experimental, n = 7) and untreated with only SCs preloaded with FITC-labeled nanoparticles (green when viewed through FITC filter). Some OVA-challenged mice (controls, n = 7). The lungs were collected 24 h postinjection of the preloaded SCs (8 × mice were injected with SCs preloaded with FITClabeled nanoparticles and then prelabeled with DiI (red 10 6 ). The SCs and lungs were placed in labeled containers with 1 ml PBS and then sonicated for 10 s by the when view through the TRITC filter and yellow when viewed through FITC filter). Organs and tissues col-Sonic Dismembrinator 60 (Fisher Scientific) to release the curcumin nanoparticles. The curcumin was then sep-lected included the lungs, spleen, thymus, liver, kidneys, pancreas, muscle, blood, and bone marrow. Some tissues arated from the nanoparticles by adding 500 µl DMSO to each container. The suspension then was centrifuged were fixed with 4% paraformaldehyde/PBS for LM morphological evaluation, some with 3% gluderalde-at 1200 rpm for 10 min and the supernatant was collected. A UV spectrum was collected from each super-hyde/PBS for TEM structural evaluation, some were flash frozen and cyosectioned for LM detection of fluo-natant sample and the specific wave length absorption assay was performed at 420 nm. rescence, and some unfixed whole organs were prepared
Data Presentation
TRITC filter (Fig. 3a ), but imaged yellow (Fig. 3b ) when viewed through the FITC filter. Means and SDs were derived from multiple UV absorbance assays values of FITC-labeled nanoparticles, Normal Mouse Lungs Following SC Injection curcumincoupled nanoparticles, prelabeled SCs (8 × 10 6 ), and SCs preloaded with labeled nanoparticles. Ab-Two outcome parameters were determined: microsorbance assays for the various labels determined in scopic observations and label detection. mouse tissues were expressed as a percentage of the to-Microscopy Observations. Prelabeled SCs were not tal amount of label deliver by the injected SCs by dividevident in the mouse spleen, liver, thymus, kidney, musing the observed absorbance value by the absorbance cle, pancreas, bone marrow, and blood 15 min or 1 h value determined for the injected SCs (8 × 10 6 ).
postinjection based on the absence of label-specific fluorescence in any of these tissues. The only tissue in which RESULTS specific SC label was detected, microscopically, was the Microscopic Observations of Labeled Sertoli Cells lung. and Image Definition At 15 min postinjection, SCs prelabeled with DiO (green) were homogeneously distributed throughout the Isolated rat SCs, in primary cell culture, aggressively and selectively phagocytosed FITC-labeled nanopar-lung, including the lower lobes (Fig. 2) , which at higher magnification appeared to be distributed in the precapil-ticles (i.e., preloaded SCs) as determined by labelspecific positive fluorescence (Fig. 1, green) in the SCs lary vasculature around alveolar sacs ( Fig. 2a , inset). SC label was not observed in the sham-injected control lung and the absence of fluorescence in control cells and contaminating peritubular cells (Fig. 1, 1a inset). At high (Fig. 2c ). SCs prelabeled with DiI and also preloaded with FITC-labeled nanoparticles were observed through-magnification, single cell suspensions of preloaded SCs demonstrated positive cytoplasmic fluorescence for the out the lungs and imaged red when viewed through the TRITC filter and yellow when view thought the FITC FITC-labeled nanoparticles when viewed through the FITC filter (Fig. 1b, inset) . When isolated SCs were pre-filter in cryosectioned lungs (Fig. 3c, d) , as was the case for SCs in vitro (Fig. 3a, b) . Cryosections from control labeled with DiO they imaged green when viewed through the FITC filter, both in vitro as well as in the lungs showed no specific label with either filter (Fig. 3c,  d , insets). lung (Fig. 2) and imaged red when prelabeled with DiI and view through the TRITC filter. When FITC-labeled At 1 h postinjection of preloaded, prelabeled SCs, unfixed lung cryosections exhibited some SC label (red) nanoparticles were preloaded in SCs and then the SCs were prelabeled with DiI, these preloaded, prelabeled when view thought the TRITC filter ( Fig. 3e ), but there was no evidence of intact SCs as evidenced by the ab-SCs in vitro imaged red when viewed through the sence of yellow fluorescent when viewed thought the tained 92% of the total load, while the liver and the kidneys contained 8% and 5%, respectively. FITC filter (Fig. 3f ). There was, however, distinctive green fluorescence (Fig. 3f ) when viewed through the At 1 h postinjection, the mean specific absorbance of labeled nanoparticles from the mouse lung of preloaded FITC filter, indicating positive detection for the FITClabeled nanoparticles. Likewise, in unfixed whole lung SCs was 2.5 ± 0.12, from liver was 0.4 ± 0.12, and from kidney was 0.2 ± 0.10. Specific UV absorbance of labels samples, positive FITC label appeared homogeneously distributed throughout the lung when viewed at lower from the spleen and lungs from control mice were not detected ( Fig. 5 ). When expressed as the percentage of magnification by fluorescent stereoscopic microscopy (Fig. 3, Exp) . As with the cyrosections, positive TRITC the total nanoparticles delivered in the injected preloaded SCs, the lungs contained 65% of the total load, label was also evident (Fig. 3, Exp) . Label was not detected by either filter in lung sections from control mice while the liver and the kidneys contained 10% and 5%, respectively ( Fig. 6 ). (Fig. 3, Cont) . Tissue processed for electron microscopy from the 1 h postinjection lung exhibited small vessels OVA-Challenged Mouse Lungs Following SC Injection and capillaries containing what appeared to be cell Curcumin-coupled nanoparticles were preloaded in membrane debris and inclusions similar in appearance SCs (8 × 10 6 ) and then delivered to the mouse lungs by to aggregated labeled nanoparticles (Fig. 4, inset) .
injection via the lateral tail vein. Lungs from SNAP-Label Detection. The number of preloaded and/or treated and untreated OVA-challenged were collected 24 prelabeled SCs assayed (8 × 10 6 ) was the same as the h postinjection. number of SCs injected into the mouse host. The spe-Microscopic Observations. Lung sections from all cific UV absorption in arbitrary units derived from SCs seven untreated OVA-challenged control mice presented preloaded with FITC-labeled nanoparticles was 4.5 ± with diffuse perivascular inflammatory cell invasion into 0.45, from SCs prelabeled with DiI was 4.7 ± 0.46, and the interstitial pulmonary space (Fig. 7a ), as previously from SCs preloaded and prelabeled was 3.8 ± 0.46 and described (11) . However, lung sections from all seven 3.7 ± 0.46, respectively.
OVA-challenged mice injected with SCs preloaded with At 15 min postinjection the mean specific UV absorcurcumin-coupled nanoparticles were clear of inflammabance of labeled nanoparticles in arbitrary units derived tory pathology 24 h postinjection as judged by the abfrom mouse lung of preloaded SCs was 3.5 ± 0.11, from sence of inflammatory cell types in the pulmonary tissue liver was 0.3 ± 0.12, and from the kidney was 0.2 ± (Fig. 7b ). 0.12. Specific UV absorbances in the spleen and lung from control mice were not detected (Fig. 5) . When ex-Label Detection. Curcumin was assayed in preloaded SCs (8 × 10 6 ) in vitro and also assayed in lungs collected pressed as the percentage of the total nanoparticles delivered in the injected preloaded SCs, the lungs con-from the OVA-challenged mice 24 h postinjection of the preloaded SCs. The mean specific wave length absor-jected OVA-challenged mice (n = 7). When expressed as the percentage of the total amount of delivered cur-bance from the preloaded SCs in vitro was 4.28 ± 0.46 and from the lungs of injected OVA-challenged mice cumin (curcumin in the injected SCs), the lungs contained ϳ90% of the total amount of curcumin injected (n = 7) was 3.72 ± 0.72. Curcumin was not detected by specific wave length absorbance in the lungs of unin- (Fig. 6 ). 
DISCUSSION
lar debris in pulmonary capillaries and the presence of liberated nanoparticles. Based on this and the detection and quantification of the nanoparticle-specific label in the Results showed that following IV injection, via the mouse lateral tail vein, prelabeled isolated rat SCs pre-lungs, these results indicate that the IV-injected rat SCs carried and then effectively delivered most of the pre-loaded with chitosan nanoparticles became entrapped in the host's deep lung and were distributed around alveoli loaded nanoparticles into and throughout the deep lung. Delivery of the anti-inflammatory compound cur-in the perialveolar sac pulmonary vasculature, and that intact SCs were not detected in other tissues and organs cumin to the deep lung by SNAP was tested in an animal model of pulmonary inflammation. Following 24 h post-such as the kidneys, thymus, and liver. At 15 min postinjection, the prelabeled, preloaded SCs appeared intact in injection of SCs preloaded with curcumin-coupled nanoparticles, all tissue sections from all treated OVA-chal-the lung based on the unique florescent imaging of these cells; and they appeared to occupy a perialveolar sac lenged mice (n = 7) showed no evidence of airway or perivascular inflammation whereas all untreated OVA-distribution throughout the organ including the lower lung. Also at 15 min postinjection, 92% of the labeled challenged mice (n = 7) retained overt perivascular pulmonary inflammation. This pilot animal experiment to nanoparticle load originally contained in the injected SCs was present in the lungs with some minimal label test the utility of the SNAP drug delivery resulted in a conspicuous therapeutic outcome, indicating the effi-detection in the liver and kidney, but absent in other tissues and organs assayed. However, at 1 h postinjec-cient delivery of curcumin to the deep lung. Although there was a conspicuous and rapid therapeutic response tion, there was no evidence of intact SCs in the lungs, although the volume of nanoparticles in the lungs re-to the SNAP delivery of curucmin, quantification of the observed therapeutic effect, safe dosing parameters, and mained at ϳ70% of the total load delivered. The absence and apparent lysis of intact SCs in the lungs was a more in-depth study are clearly necessary to better verify and define these observations. supported by the electron microscopic detection of cellu- Figure 6 . Percent of total of DiI label (Sertoli cells, UV at 553 nm) and FITC label (nanoparticles, UV 488 nm) 1 h following IV injection of preloaded, prelabeled rat Sertoli cells (SCs) in the mouse host, and percent of total curcumin label (UV at 420 nm) 24 h following IV injection of preloaded rat SCs into the mouse host. Following 1 h postinjection only 26% of SC label was detected in the mouse lungs and no SC label was detected in other organs and tissues tested, whereas 65% of the delivered nannoparticles was detected in the lungs with some detection in the kidney (10%) and liver (5%). Twenty-four hours postinjection, 87% of the curcumin label was detected in the lungs with no detection in other tissues and organs tested. None of the labels were detected in uninjected control mouse lungs. Nanoparticles such as those constructed of chitosan into the peripheral vasculature, which then go directly to the pulmonary vasculature, may provided a effective and utilized in this project have been found to be useful carriers for sustained drug release for up to 96 h (12, 13) alternative to current methodologies and overcome the limitations inherent in the pulmonary delivery route. The and there are currently several administration routes for their pulmonary delivery to the lungs (12, 13, 21, 22) . delivery of 87% of the curcumin load to and throughout the lungs and especially the deep lung by SNAP delivery However, by this route, optimal distribution of therapeutic nanoparticles to the entire airway, especially the deep is a significant advantage in drug utilization, particularly in situations where airway delivery is urgent and limited lung, can be limited by deposition in the oropharynx, inappropriate breathing patterns, particle size, particle by severe airway obstruction or interstitial edema. These data suggest that SNAP delivery may provide alternative aggregation, and their exhalation after inspiration (2, 11, 21) . The SNAP delivery of drugs can overcome these means to deliver high local concentrations of other agents such as immunosuppressive drugs for lung trans-limitations, therefore optimizing high-density delivery and retention of drugs into and throughout the organ plantation therapy. Additional utilization of this methodology, when fully verified, could be of benefit in condi-without accumulation in other organ systems. Because isolated SCs aggressively phagocytose nanoparticles, are tions such as ARDS, status asthmaticus, pulmonary hypertension, posttransplantation complications follow-self-immunoprotective (5, 20) , and have not been shown to elicit an inflammatory response by the host following ing lung transplantation where inhaled or oral drug delivery is impractical, lung cancer, or where systemic de-transplantation (8, 19) , results of this study indicated that the utilization of SNAP drug delivery offers a safe and livery of drugs induces unacceptable drug toxicity. effective therapeutic modality for the targeted delivery REFERENCES of drug-specific nanoparticles to the deep lung by this unique cell type.
